Estimation de l'Insee fin décembre sur les prix à la consommation en France
|
Accueil > Actualité
Roche: priority review in Duchenne myopathy
(CercleFinance.com) - Sarepta Therapeutics announced on Monday that the US FDA haz granted a priority review to its marketing application for SRP-9001, an experimental gene therapy for boys with Duchenne muscular dystrophy that the company is developing in collaboration with Roche.
In its statement, the US biotech said the health agency has set a target date of 29 May 2023 for the product's approval. In December 2019, Roche entered into a partnership with Sarepta for the moxeparvovec delandistrogen gene therapy (SRP-9001) aimed at accelerating its availability outside the US. Copyright (c) 2022 CercleFinance.com. All rights reserved. |
03/02/2023 17:16
Rocheprofite d'un rebond après les bénéfices 2022 03/02/2023 16:58 ScorNorges Bank dépasse les 5% du capital 03/02/2023 16:42 Modernanouveaux essais cliniques de vaccins anticancéreux 03/02/2023 16:21 Amazondéçoit avec ses prévisions, l'action trébuche 03/02/2023 15:45 Merckun traitement a atteint le critère principal de survie 03/02/2023 15:02 Altur InvestissementSuffren Holding dépasse les deux tiers Tous les articles sociétés |
